A paradigm shift in pediatric vision screening with blinq.
blinq., a paradigm shift in pediatric vision screening
Rebion manufactures innovative devices for definitively identifying life-altering diseases that manifest from functional impairments in the brain, most notably amblyopia (lazy eye). Support the spirit of instrument-based vision screening initiatives with direct detection of amblyopia.
Why is direct detection so important?
Clinical studies funded by NIH/NEI have shown that screening with blinq. is a dramatically more accurate approach to measuring for amblyopia than methods which merely collect data on amblyopic "risk factors." Greater accuracy leads to a reduction in care costs while improving patient outcomes.
blinq. screening may be reimburseable under category III CPT code 07X6T "retinal polarization scan, ocular screening with on-site automated results, bilateral"
Brands: Rebion's "blinq." implements proprietary Neural Performance Scanning (NPS)